Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases

Conclusions: Using a model that incorporated the full range of HPV-related diseases, and the latest cervical cancer screening practices, we found that switching from bivalent to nonavalent vaccination would be considered cost-effective in Norway.PMID:37608730 | DOI:10.1080/13696998.2023.2250194

Source: Journal of Medical Economics - August 23, 2023 Category: Health Management Authors: Ibrahim Diakite Sylvi Nguyen Ugne Sabale Andrew Pavelyev Kunal Saxena Athar Ali Tajik Wei Wang Cody Palmer Source Type: research